Which AI agents work with Es Cushing Surgical Resection Bilateral Adrenal Disorders?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Who published Es Cushing Surgical Resection Bilateral Adrenal Disorders?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Es Cushing Surgical Resection Bilateral Adrenal Disorders by dromlakhani

Name: Es Cushing Surgical Resection Bilateral Adrenal Disorders
Rating: 4.2 (5 reviews)
Author: dromlakhani

Es Cushing Surgical Resection Bilateral Adrenal Disorders

This skill recommends bilateral adrenalectomy for patients with Cushing's syndrome when bilateral adrenal pathology is confirmed as the source of hypercortisolism. Clinical triggers include bilateral macronodular adrenal hyperplasia (BMAH), bilateral adrenal adenomas, or bilateral adrenal carcinoma identified by imaging.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Surgical Resection of Bilateral Adrenal Disorders for Cushing's Syndrome

STEP 1 — Gather Information

Confirm overt Cushing's syndrome with elevated 24‑h urinary free cortisol or late‑night salivary cortisol; measure plasma ACTH to distinguish ACTH‑independent (<5 pg/mL) from ACTH‑dependent sources; obtain adrenal protocol CT or MRI to assess size, number, and characteristics of adrenal lesions; consider adrenal venous sampling if lateralization is uncertain.

STEP 2 — Rule In / Rule Out

If plasma ACTH is suppressed (<5 pg/mL) indicating an ACTH‑independent (adrenal) source, proceed to evaluate bilateral disease; if ACTH is not suppressed, rule out a primary adrenal etiology and pursue pituitary or ectopic sources instead.

STEP 3 — Classify or Stratify

Classify bilateral adrenal pathology: bilateral macronodular adrenal hyperplasia (multiple nodules >1 cm on both sides), bilateral adenomas (distinct nodules), or bilateral carcinoma (irregular, invasive lesions); unilateral dominant lesion redirects to unilateral adrenalectomy.

STEP 4 — Decide

Recommend bilateral laparoscopic adrenalectomy as definitive treatment; for patients with prohibitive surgical risk or who decline surgery, consider medical therapy to block aberrant hormone receptors (e.g., mifepristone, ketoconazole) as a bridge or palliative option.

Clinical Guardrails / Mimics / Pitfalls

Do not perform unilateral adrenalectomy when bilateral disease is confirmed; avoid relying solely on medical therapy for bilateral adrenal carcinoma; ensure lifelong glucocorticoid and mineralocorticoid replacement postoperatively; monitor for Nelson syndrome if the patient has a history of Cushing’s disease; do not delay surgery in patients with life‑threatening hypercortisolism (e.g., severe infection, thrombosis, psychosis).

Concrete Clinical Example

A 48‑year‑old woman presents with weight gain, hypertension, and undetectable ACTH; CT shows 3.5 cm nodules in both adrenal glands; biochemical testing confirms ACTH‑independent Cushing’s syndrome; she undergoes bilateral laparoscopic adrenalectomy, postoperative cortisol is undetectable, and she is started on hydrocortisone 20 mg/day and fludrocortisone 0.1 mg/day.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., Endocrine Society, 2015, DOI:10.1210/jc.2015-1818

---name: es-cushing-surgical-resection-bilateral-adrenal-disordersdescription: This skill recommends bilateral adrenalectomy for patients with Cushing's syndrome when bilateral adrenal pathology is confirmed as the source of hypercortisolism. Clinical triggers include bilateral macronodular adrenal hyperplasia (BMAH), bilateral adrenal adenomas, or bilateral adrenal carcinoma identified by imaging.---# Surgical Resection of Bilateral Adrenal Disorders for Cushing's Syndrome## STEP 1 — Gather InformationConfirm overt Cushing's syndrome with elevated 24‑h urinary free cortisol or late‑night salivary cortisol; measure plasma ACTH to distinguish ACTH‑independent (<5 pg/mL) from ACTH‑dependent sources; obtain adrenal protocol CT or MRI to assess size, number, and characteristics of adrenal lesions; consider adrenal venous sampling if lateralization is uncertain.## STEP 2 — Rule In / Rule OutIf plasma ACTH is suppressed (<5 pg/mL) indicating an ACTH‑independent (adrenal) source, proceed to evaluate bilateral disease; if ACTH is not suppressed, rule out a primary adrenal etiology and pursue pituitary or ectopic sources instead.## STEP 3 — Classify or StratifyClassify bilateral adrenal pathology: bilateral macronodular adrenal hyperplasia (multiple nodules >1 cm on both sides), bilateral adenomas (distinct nodules), or bilateral carcinoma (irregular, invasive lesions); unilateral dominant lesion redirects to unilateral adrenalectomy.## STEP 4 — DecideRecommend bilateral laparoscopic adrenalectomy as definitive treatment; for patients with prohibitive surgical risk or who decline surgery, consider medical therapy to block aberrant hormone receptors (e.g., mifepristone, ketoconazole) as a bridge or palliative option.## Clinical Guardrails / Mimics / PitfallsDo not perform unilateral adrenalectomy when bilateral disease is confirmed; avoid relying solely on medical therapy for bilateral adrenal carcinoma; ensure lifelong glucocorticoid and mineralocorticoid replacement postoperatively; monitor for Nelson syndrome if the patient has a history of Cushing’s disease; do not delay surgery in patients with life‑threatening hypercortisolism (e.g., severe infection, thrombosis, psychosis).## Concrete Clinical ExampleA 48‑year‑old woman presents with weight gain, hypertension, and undetectable ACTH; CT shows 3.5 cm nodules in both adrenal glands; biochemical testing confirms ACTH‑independent Cushing’s syndrome; she undergoes bilateral laparoscopic adrenalectomy, postoperative cortisol is undetectable, and she is started on hydrocortisone 20 mg/day and fludrocortisone 0.1 mg/day.**Source:** Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., Endocrine Society, 2015, DOI:10.1210/jc.2015-1818

Frequently asked questions